What do systematic reviews say?

Nebulized budesonide vs viscous budesonide

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nebulized budesonide vs viscous budesonide

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Very low

Viaskin milk patch vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Viaskin milk patch vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 9 participants
  Low

Viaskin milk patch vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Viaskin milk patch vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 9 participants
  Low

Viaskin milk patch vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Viaskin milk patch vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Low

Viaskin milk patch vs placebo

Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.12 [0.05, 23.99]
  1 study · 20 participants
  Low

Leukotriene receptor antagonist vs placebo

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.68 [0.66, 4.28]
  1 study · 41 participants
  Very low

Fecal microbiota transplantation vs control

Fecal microbiota transplantation may leads to higher induction of clinical remission in UC at longest compared with control (low certainty).

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 1.79 [1.13, 2.84]
  10 studies · 468 participants
  Low

Fecal microbiota transplantation vs control

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fecal microbiota transplantation vs control

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fecal microbiota transplantation vs control

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fecal microbiota transplantation vs control

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fecal microbiota transplantation vs control

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fecal microbiota transplantation vs control

It is very uncertain whether fecal microbiota transplantation changes serious adverse events with use of FMT for induction of remission in… compared with control (very low certainty).

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 1.77 [0.88, 3.55]
  10 studies · 468 participants
  Very low

Fecal microbiota transplantation vs control

Fecal microbiota transplantation showed no clear difference in any adverse events with use of FMT for induction of remission in UC… compared with control (low certainty).

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 0.99 [0.85, 1.16]
  9 studies · 417 participants
  Low

Fecal microbiota transplantation vs control

Fecal microbiota transplantation showed no clear difference in induction of endoscopic remission in UC at longest compared with control (low certainty).

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 1.45 [0.64, 3.29]
  5 studies · 285 participants
  Low

Fecal microbiota transplantation vs control

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 131 participants
  Very low